[
  {
    "ts": "2025-11-18T04:43:10+00:00",
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044310480.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "93b630e7-811e-35ca-9447-b0ebfd6daa97",
      "content": {
        "id": "93b630e7-811e-35ca-9447-b0ebfd6daa97",
        "contentType": "STORY",
        "title": "1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid",
        "description": "",
        "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
        "pubDate": "2025-11-18T04:43:10Z",
        "displayTime": "2025-11-18T04:43:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/615e7de451b4e3d7091635c16662c61f",
          "originalWidth": 2400,
          "originalHeight": 1198,
          "caption": "QLYS Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tvt.bhG5N6JVrKhmjNYxcA--~B/aD0xMTk4O3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/615e7de451b4e3d7091635c16662c61f.cf.webp",
              "width": 2400,
              "height": 1198,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9BTQDaynRaVr6yr6uECGyg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/615e7de451b4e3d7091635c16662c61f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044310480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-044310480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "QLYS"
            },
            {
              "symbol": "KBH"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T10:30:00+00:00",
    "headline": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
    "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
    "url": "https://www.wsj.com/health/pharma/the-weight-loss-craze-is-about-to-mint-a-trillion-dollar-company-f92d51d0?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "ac2e96e5-a067-3c02-a2cf-3819f053faab",
      "content": {
        "id": "ac2e96e5-a067-3c02-a2cf-3819f053faab",
        "contentType": "STORY",
        "title": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
        "description": "",
        "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
        "pubDate": "2025-11-18T10:30:00Z",
        "displayTime": "2025-11-18T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ac2e96e5-a067-3c02-a2cf-3819f053faab/the-weight-loss-craze-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BONe.IvmYz1PI80IiJvYow--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lZg8ZTfmPAKqUBBdR2wmmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/the-weight-loss-craze-is-about-to-mint-a-trillion-dollar-company-f92d51d0?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T13:45:45+00:00",
    "headline": "Jim Cramer Says Amgen (AMGN)’s New Drug Has Good Data",
    "summary": "We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed. Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently. Most of his discussions surround the firm’s Repatha drug that aims to reduce cholesterol and prevent […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-says-amgen-amgn-134545291.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "70fe250f-8d40-382a-96f9-60148ef042c8",
      "content": {
        "id": "70fe250f-8d40-382a-96f9-60148ef042c8",
        "contentType": "STORY",
        "title": "Jim Cramer Says Amgen (AMGN)’s New Drug Has Good Data",
        "description": "",
        "summary": "We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed. Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently. Most of his discussions surround the firm’s Repatha drug that aims to reduce cholesterol and prevent […]",
        "pubDate": "2025-11-18T13:45:45Z",
        "displayTime": "2025-11-18T13:45:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1e9120b21df9d4584216be519950b41a",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "Jim Cramer Says Amgen (AMGN)'s New Drug Has Good Data",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fMTKP7t.2d.zV8tkJ89T9A--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1e9120b21df9d4584216be519950b41a.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/02t2dAWp2fmON9uUD0DVog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1e9120b21df9d4584216be519950b41a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-amgen-amgn-134545291.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-amgen-amgn-134545291.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:37:00+00:00",
    "headline": "Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma",
    "summary": "The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem",
    "url": "https://finance.yahoo.com/news/renal-anemia-market-research-report-153700490.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "9629426b-0c7a-35b3-9ec7-3493d805a1a3",
      "content": {
        "id": "9629426b-0c7a-35b3-9ec7-3493d805a1a3",
        "contentType": "STORY",
        "title": "Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma",
        "description": "",
        "summary": "The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem",
        "pubDate": "2025-11-18T15:37:00Z",
        "displayTime": "2025-11-18T15:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/renal-anemia-market-research-report-153700490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/renal-anemia-market-research-report-153700490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SDZ.SW"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GSK.L"
            },
            {
              "symbol": "AKBA"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:20:00+00:00",
    "headline": "Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion",
    "summary": "The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio",
    "url": "https://finance.yahoo.com/news/microscopic-polyangiitis-market-research-report-152000128.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "5a956957-cf27-33cb-bbcd-a1600c03f789",
      "content": {
        "id": "5a956957-cf27-33cb-bbcd-a1600c03f789",
        "contentType": "STORY",
        "title": "Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion",
        "description": "",
        "summary": "The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio",
        "pubDate": "2025-11-18T15:20:00Z",
        "displayTime": "2025-11-18T15:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/microscopic-polyangiitis-market-research-report-152000128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/microscopic-polyangiitis-market-research-report-152000128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "TEVA.TA"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "BAX"
            },
            {
              "symbol": "IFRX"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]